GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » 14-Day RSI

Haisco Pharmaceutical Group Co (SZSE:002653) 14-Day RSI : 39.24 (As of Jan. 18, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-01-18), Haisco Pharmaceutical Group Co's 14-Day RSI is 39.24.

The industry rank for Haisco Pharmaceutical Group Co's 14-Day RSI or its related term are showing as below:

SZSE:002653's 14-Day RSI is ranked better than
73.24% of 1521 companies
in the Biotechnology industry
Industry Median: 44.93 vs SZSE:002653: 39.24

Competitive Comparison of Haisco Pharmaceutical Group Co's 14-Day RSI

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haisco Pharmaceutical Group Co's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's 14-Day RSI falls into.



Haisco Pharmaceutical Group Co  (SZSE:002653) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co  (SZSE:002653) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Haisco Pharmaceutical Group Co 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co Headlines

No Headlines